Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results forSHP
0.00 (0.00%)
Feb 16 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 3,034.00 - 5,067.00
Open     -
Vol / Avg. 0.00/3.11M
Mkt cap 29,131.25M*
P/E 6.19
Div/yield 21.46*
EPS 5.18*
Shares 910.04M
Beta     -
Inst. own     -
Apr 26, 2018
Q1 2018 Shire PLC Earnings Release Add to calendar
Apr 25, 2018
Shire PLC Annual Shareholders Meeting (Estimated) - 2:45pm BST - Add to calendar
Feb 14, 2018
Full Year 2017 Shire PLC Earnings Call - Webcast
Feb 14, 2018
Full Year 2017 Shire PLC Earnings Release
Jan 8, 2018
Shire PLC at JPMorgan Healthcare Conference (Q&A Session)
Jan 8, 2018
Shire PLC at JPMorgan Healthcare Conference - Webcast

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 132.26% 43.73%
Operating margin 20.51% 16.19%
EBITD margin - 37.54%
Return on average assets 32.52% 9.84%
Return on average equity 63.92% 20.37%
Employees 23,906 -
CDP Score - B


Miesian Plaza 50-58 Baggot Street Lower, Block 2
+353-1-6096000 (Phone)
+44-1256-894708 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 59
John Miller Interim Chief Financial Officer
Joanne Cordeiro Chief Human Resource Officer
Andreas Busch Ph.D. Executive Vice President - Head of Research and Development, Chief Scientific Officer
Age: 54
Gisele Dion Chief Accounting Officer, Corporate Controller
Age: 51
William Mordan General Counsel, Company Secretary
Age: 47
Howard Mayer M.D. Chief Medical Officer
Perry Sternberg Head - U.S. Commercial
Age: 48
Kim Stratton Head - International Commercial
Age: 56
Philip J. Vickers Head - Research and Development
Age: 56